Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: Experience of an Italian drug-surveillance center

Journal of Cutaneous Medicine and Surgery

Volumn 10, Issue 1, 2006, Pages 31-35

  Atzori, Laura ^a,b   Pinna, Anna Luisa ^a   Pau, Monica ^a   Aste, Natalia ^a   Zucca, Myriam ^a   Ferreli, Caterina ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Clinica Dermatologica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CELECOXIB; ETORICOXIB; ROFECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

ADULT; AGED; ALGORITHM; ANGIONEUROTIC EDEMA; ARTHROPATHY; ARTICLE; CLINICAL ARTICLE; DRUG ERUPTION; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; ITALY; KNEE OSTEOARTHRITIS; LEUKOCYTOCLASTIC VASCULITIS; LOW BACK PAIN; MACULOPAPULAR RASH; MALE; PRIORITY JOURNAL; PRURITUS; PURPURIC RASH; RASH; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; SKIN MANIFESTATION; SKIN PIGMENTATION; SPONDYLOSIS; URTICARIA; WORLD HEALTH ORGANIZATION; HEALTH SURVEY; MIDDLE AGED; PROSPECTIVE STUDY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CYCLOOXYGENASE 2 INHIBITORS; DRUG ERUPTIONS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES;

EID: 35748952855     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/7140.2006.00012     Document Type: Article

References (14)

1. Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatology 1993;186:164-9.
2. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
3. Shapiro LE, Knowles SR, Weber E, et al. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf 2003;26:187-95.
4. Picado P. COX-2 specific inhibitors in NSAID-intolerant patients. Int J Immunopathol Pharmacol 2003;16:11-6.
5. Senna G, Bilo MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Allerg Immunol 2004;36:215-8.
6. Knowles S, Shapiro L, Shean NH. Should celecoxib be contra-indicated in patients who are allergic to sulfonamides? Druf Saf 2001;24:239-42.
7. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
8. Marques S, Milpied B, Foulc P, et al. Severe cutaneous drug reactions to celecoxib. Ann Dermatol Venereol 2003;130:1051.
9. Murr D, Bocquet H, Lelouet H, et al. Adverse cutaneous reaction to celecoxib: 6 cases. Ann Dermatol Venereol 2003;130:519.
10. Schneider F, Meziani F, Chartier C, et al. Fatal allergic vasculitis associated with celecoxib. Lancet 2002;359:852-3.
11. Report of a WHO meeting. World Health Organ Rep Series 1972;498:1-25.
12. Verbeiren S, Morant C, Charlanne H, et al. Celecoxib-induced toxic skin reaction with positive patch test. Ann Dermatol Venereol 2002;129:203-5.
13. Litt JZ. Pocketbook of drug eruptions and interactions. New York: The Parthenon Publishing Group; 1999.
14. Mahajan A, Sharma R. COX-2 selective nonsteroidal anti-inflammatory drugs: current status. J Assoc Physicians India 2005;53:200-4.